Clinical Trial Update: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating perioperative mFOLFOX6 plus pembrolizumab for potentially resectable gastroesophageal junction and stomach adenocarcinoma has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma
• Stomach Adenocarcinoma

Drugs mentioned

• MFOLFOX6
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Weijing Sun, MD, FACP | Conditions: Adenocarcinoma, Stomach Cancer | Phase 2 | Status: WITHDRAWN